Immuneering to Present at the Piper Sandler 36th Annual Healthcare Conference
Immuneering to Present at the Piper Sandler 36th Annual Healthcare Conference
The presentations will be webcast live and archived in the Investor Relations section of Immuneering's website at Events & Presentations | Immuneering Corporation.CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference, which is taking place at the Lotte New York Palace in New York City from December 3-5, 2024, to discuss the company's pipeline, platform, and business strategy. Participating will be Ben Zeskind, Chief Executive Officer, Harold "E.B." Brakewood, Chief Business Officer and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.
CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference, which is taking place at the Lotte New York Palace in New York City from December 3-5, 2024, to discuss the company's pipeline, platform, and business strategy. Participating will be Ben Zeskind, Chief Executive Officer, Harold "E.b." Brakewood, Chief Business Officer and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.
Format: Fireside Chat and 1x1 Investor Meetings
形式：现场访谈和1x1投资者会议
Date/Time: December 5 from 1:00 pm – 1:25 pm ET
Date/Time: December 5 from 1:00 pm – 1:25 pm ET
The presentations will be webcast live and archived in the Investor Relations section of Immuneering's website at Events & Presentations | Immuneering Corporation.
The presentations will be webcast live and archived in the Investor Relations section of Immuneering's website at Events & Presentations | Immuneering Corporation.
About Immuneering Corporation
关于Immuneering Corporation
Immuneering is a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The Company aims to achieve universal activity through Deep Cyclic Inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering's lead product candidate, IMM-1-104, is an oral, once-daily Deep Cyclic Inhibitor currently in a Phase 2a trial in patients with advanced solid tumors including those harboring RAS mutations. IMM-6-415 is an oral, twice-daily Deep Cyclic Inhibitor currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS or RAF mutations. The company's development pipeline also includes several early-stage programs. For more information, please visit .
Immuneering是一家处于临床阶段的肿瘤公司，旨在开发和商业化面向癌症患者群体的通用RAS/RAF药物，最初的目标是开发通用性RAS疗法。该公司通过对MAPk途径的深层周期性抑制，影响癌细胞而不伤及健康细胞，旨在实现通用活性。Immuneering的主导产品候选药物IMm-1-104是一种口服、每日一次的深层周期性抑制剂，目前正在进行IIa期试验，对象为患有晚期实体肿瘤（包括携带RAS突变的肿瘤）的患者。IMm-6-415是一种口服、每天两次的深层周期性抑制剂，目前正在进行I/IIa期试验，对象为患有RAS或RAF突变的晚期实体肿瘤患者。该公司的开发管道还包括几个早期项目。更多信息，请访问。
Media Contact:
Gina Nugent
gina@nugentcommunications.com
媒体联系：
Gina Nugent
gina@nugentcommunications.com
Investor Contact:
Laurence Watts
619-916-7620
laurence@newstreetir.com
投资者联系人：
劳伦斯·瓦茨
619-916-7620
laurence@newstreetir.com
译文内容由第三方软件翻译。
